Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900491 | 0.86 | CETP (0.39) | GPR3PDE2AFFAR4FFAR1SCN5A | |
| SCHEMBL18355878 | 0.83 | KIF11 (0.40) | GPR3FFAR4KIF11HTR2ASLC6A4 | |
| SCHEMBL900910 | 0.83 | PDE2A (0.47) | GPR3PDE2AFFAR4FFAR1SCN5A | |
| SCHEMBL171112 | 0.83 | GPR3 (0.49) | GPR3PDE2AFFAR4SCN5AKIF11 | |
| SCHEMBL30867033 | 0.83 | GPR3 (0.49) | GPR3PDE2AFFAR4SCN5AKIF11 | |
| SCHEMBL14534817 | 0.79 | GPR3 (0.46) | GPR3FFAR4FFAR1SCN5AKIF11 | |
| SCHEMBL15889082 | 0.78 | CETP (0.35) | GPR3PDE2AFFAR4FFAR1HTR2A | |
| SCHEMBL2526660 | 0.78 | GPR3 (0.45) | GPR3PDE2AFFAR4SCN5AKIF11 | |
| SCHEMBL1221631 | 0.78 | GPR3 (0.45) | GPR3FFAR4SCN5AKIF11CYP1A2 | |
| SCHEMBL10153891 | 0.78 | FFAR4 (0.49) | GPR3PDE2AFFAR4FFAR1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11254666-B2 | Compound as GLS1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3715347-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| WO-2012041858-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| WO-2010004215-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
| EP-0075146-B1 | BENZYL ESTERS WITH FLUOROSUBSTITUTED ETHER GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR UTILISATION AS INSECTICIDES | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0075146-A1 | Benzyl esters with fluorosubstituted ether groups, process for their preparation and their utilisation as insecticides | BAYER AG (DE) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | GPR3 1104/4885PDE2A 2400/4885FFAR4 2545/4885 |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CNR1, CNR2, GPR18 | GPR3 89/4885PDE2A 4108/4885FFAR4 243/4885 |
| US-11254666-B2 | Compound as GLS1 inhibitor | GLS, GLS2, GLB1 | GPR3 942/4885PDE2A 2068/4885FFAR4 2401/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | GPR3 2866/4885PDE2A 4751/4885FFAR4 2899/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | GPR3 2932/4885PDE2A 1380/4885FFAR4 2998/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | GPR3 1429/4885PDE2A 4171/4885FFAR4 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.